0I5R Stock Overview
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LadRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.00 |
| 52 Week High | US$17.70 |
| 52 Week Low | US$1.00 |
| Beta | 1.62 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.69% |
| 5 Year Change | n/a |
| Change since IPO | -99.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I5R | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | -0.9% |
| 1Y | n/a | -30.5% | -1.8% |
Return vs Industry: Insufficient data to determine how 0I5R performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0I5R performed against the UK Market.
Price Volatility
| 0I5R volatility | |
|---|---|
| 0I5R Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0I5R has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0I5R's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 3 | Stephen Snowdy | www.ladrxcorp.com |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company’s Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer.
LadRx Corporation Fundamentals Summary
| 0I5R fundamental statistics | |
|---|---|
| Market cap | US$925.82k |
| Earnings (TTM) | US$176.65k |
| Revenue (TTM) | n/a |
5.6x
P/E Ratio0.0x
P/S RatioIs 0I5R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I5R income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$176.65k |
| Earnings | US$176.65k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0I5R perform over the long term?
See historical performance and comparison